Physician profile
Paul Basuk
NPI 1033194675
$12,374.80
in general payments reported to CMS, 2019-2025
37 companies · $2,006 in 2025
The $2,006 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,191 · 2020: $899 · 2021: $1,838 · 2022: $2,209 · 2023: $2,138 · 2024: $2,094 · 2025: $2,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,137 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,137.04 |
| Education | $100.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,706.89 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $2,448.18 | 2019-2025 | Linzess, Skyrizi, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,336.65 | 2019-2025 | Entyvio |
| Qol Medical, LLC | $950.46 | 2019-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $739.44 | 2019-2025 | Tremfya, Stelara |
| Celgene Corporation | $718.62 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $597.12 | 2019-2024 | Dificid, Recarbrio, Zerbaxa |
| Pfizer INC. | $297.58 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $272.26 | 2019-2022 | |
| Daiichi Sankyo INC. | $247.24 | 2021-2023 | Injectafer |
| Genzyme Corporation | $242.88 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $205.85 | 2020-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $197.65 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $164.73 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $148.31 | 2024-2025 | Vowst |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Basuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.